O Ðáó. åîïìïëïãåßôáé...

Boy ÇÔÁÍ ËÉÃÏ ÐÑÉÍ ÔÏ ÐÁÓ×Á ÖÅÔÏÓ ÏÔÁÍ ÅÂÃÁËÁ ÅÍÁ ÅËÊÏÓ ÓÔÁ ÃÅÍÍÇÔÉÊÁ ÌÏÕ ÏÑÃÁÍÁ.

ÅÍÔ¢ÎÅÉ ÁÖÏÕ ÔÏ ÁÖÇÓÁ ÃÉÁ ÁÑÊÅÔÏ ÊÁÉÑÏ ÊÁÍÏÍÔÁÓ ÔÁ ÄÉÊÁ ÌÏÕ ÃÉÁÔÑÏÓÏÖÉÁ, ÊÑÅÌÅÓ Ê.Ô.Ë. ÁÐÏÖÁÓÉÓÁ ÍÁ ÐÁÙ ÓÅ ÅÍÁ ÍÏÓÏÊÏÌÅÉÏ ÃÉÁ ÍÁ ÄÙ ÔÉ ÅÉÍÁÉ.

ÄÅÍ ÖÁÍÔÁÆÏÌÏÕÍ ÌÅ ÔÉÐÏÔÁ ÏÔÉ ÌÐÏÑÅÉ ÍÁ ÅÉÍÁÉ ÁÕÔÏ.
ÅÉÌÁÉ ÐÁÍÔÑÅÌÅÍÏÓ ÅÄÙ ÊÁÉ 4 ×ÑÏÍÉÁ ÊÁÉ Å×Ù ÌÉÁ ÕÃÉÅÓÔÁÔÇ ÊÏÑÏÕËÁ 2 ÅÔÙÍ.

ÓÔÉÓ ÅÎÅÔÁÓÅÉÓ ÐÏÕ ÅÊÁÍÅ Ç ÃÕÍÁÉÊÁ ÌÏÕ ÓÔÇÍ ÅÃÊÕÌÏÓÕÍÇ ÄÅÍ ÅÄÅÉ×ÍÅ ÔÉÐÏÔÁ, ÃÉÁÔÉ ÅÊÁÍÅ TEST ÊÁÉ ÃÉÁ HIV.

Ï ÃÉÁÔÑÏÓ ÌÏÕ ÅÉÐÅ ÐÙÓ ÌÁËËÏÍ ÅÉÍÁÉ ÅÑÐÇÓ, ÁËËÁ ÍÁ ÊÁÍÙ ÊÁÉ ÊÁÐÏÉÅÓ ÁËËÅÓ ÅÎÅÔÁÓÅÉÓ ÌÅÓÁ ÓÔÉÓ ÏÐÏÉÅÓ ÇÔÁÍ ÊÁÉ ÃÉÁ ÔÏÍ HIV.
ÔÅËÉÊÁ ÔÉÓ ÅÊÁÍÁ.
ÊÁÉ ÏÔÁÍ ÐÇÃÁ ÓÔÏ ÅÑÃÁÓÔÇÑÉÏ, ÁÊÏÕÓÁ ÐÙÓ ÅÉÌÁÉ ÈÅÔÉÊÏÓ ÊÁÉ ÌÁËÉÓÔÁ ÔÏ ÉÉÊÏ ÖÏÑÔÉÏ ÌÏÕ ÇÔÁÍ 50 ÖÏÑÅÓ ÐÁÍÙ ÁÐÏ ÔÏ ÖÕÓÉÏËÏÃÉÊÏ.

ÔÑÅËÁÈÇÊÁ ÊÁÉ Ç ÌÏÍÇ ÌÏÕ ÓÊÅØÇ ÃÉÁ ÌÅÑÅÓ HÔAN Ç ÁÕÔÏÊÔÏÍÉÁ ÁËËÁ ÓÊÅÖÔÏÌÏÕÍ ÐÙÓ ÔÏ ÁÃÃÅËÏÕÄÉ ÌÏÕ ÌÅ ÅÉ×Å ÁÍÁÃÊÇ ÅÓÔÙ ÊÁÉ ÌÉÁ ÙÑÁ ÆÙÇÓ ÁÊÏÌÁ ÍÁ ÌÏÕ ÅÌÅÍÅ.
ÐÇÃÁ ÓÔÏÍ ÃÉÁÔÑÏ ÌÅ ÔÉÓ ÅÎÅÔÁÓÅÉÓ ÊÁÉ ÁÑ×ÉÓÅ ÍÁ ÌÅ ÑÙÔÁÅÉ ÄÉÁÖÏÑÁ ÏÐÙÓ ÓÅÎÏÕÁËÉÊÇ ÆÙÇ ÊÔË.
ÔÏÕ ÅÉÐÁ ÏÔÉ ÅÉÌÁÉ STRAIGHT, ÐÁÍÔÑÅÌÅÍÏÓ, ÌÅ ÐÁÉÄÉ ÊÁÉ ÅÑÙÔÉÊÇ ÆÙÇ ÐÏËÕ ÖÕÓÉÏËÏÃÉÊÇ. ÍÁÑÊÙÔÉÊÁ ÐÏÔÅ.
ÁÕÔÅÓ ÇÔÁÍ ÏÉ ÁÐÁÍÔÇÓÅÉÓ ÐÏÕ ÐÇÑÅ ÊÁÉ ÏÌÙÓ ÊÏËËÇÓÁ HIV!

ÊÁÍÁÌÅ ÅÎÅÔÁÓÅÉÓ ÃÉÁ ÍÁ ÄÏÕÌÅ ÔÁ CD4 ÊÁÉ Ç ÁÐÁÍÔÇÓÇ ÁÑÃÇÓÅ ÌÏÍÏ ÄÕÏ ÌÅÑÅÓ.
ÔÁ CD4 ʾÔÔÁÑÁ ÇÔÁÍ 120 ÊÁÉ ÔÏ ÉÉÊÏ ÖÏÑÔÉÏ ÇÔÁÍ 20000.
ÏÕÔÅ Ï ÃÉÁÔÑÏÓ ÄÅÍ ÔÏ ÐÉÓÔÅÕÅ, ÁËËÁ ÊÁÐÏÉÁ ÁÐÏ ÔÁ ÓÕÌÐÔÙÌÁÔÁ ÐÏÕ ÔÏÕ ÅÄÅÉÎÁ ÔÏÍ ÅÐÅÉÓÁÍ ÏÔÉ ÏÉ ÅÎÅÔÁÓÅÉÓ ÅÉÍÁÉ ÓÙÓÔÅÓ.

ÁÑ×ÉÓÁ ÁÌÅÓÙÓ ÔÁ ÖÁÑÌÁÊÁ ÊÁÉ ÏËÁ ÐÁÍÅ ÊÁËÁ.
ÔÁ CD4 ÐÇÃÁÍ 280 ÊÁÉ Ï ÃÉÁÔÑÏÓ ËÅÅÉ ÏÔÉ ÏËÁ ÐÁÍÅ ÊÁÔÅÕ×ÇÍ.

ÓÁÓ ÔÁ ÅÃÑÁØÁ ÏËÁ ÁÕÔÁ Ï×É ÃÉÁ ÍÁ ÓÁÓ ÊÏÕÑÁÓÙ, ÁËËÁ ÃÉÁ ÍÁ ÊÁÔÁËÁÂÏÕÍ ÔÁ ÍÅÁ ÐÁÉÄÉÁ ÊÕÑÉÙÓ ÐÏÕ ÌÐÁÉÍÏÕÍ ÅÄÙ ÌÏËÉÓ ÌÁÈÁÉÍÏÕÍ ÏÔÉ ÅÉÍÁÉ ÈÅÔÉÊÏÉ, ÃÉÁÔÉ ÅÔÓÉ ÅÊÁÍÁ ÊÉ ÅÃÙ ÊÁÉ ÁÐÏ ÅÄÙ ÅÐÁÉÑÍÁ ÊÏÕÑ¢ÃÉÏ, ÃÉÁÔÉ ÇÎÅÑÁ ÐÏËÕ ËÉÃÁ ÃÉÁ ÔÏÍ HIV, ÍÁ ÌÇÍ ÖÏÂÏÕÍÔÁÉ ÊÁÉ ÍÁ EXOÕÍ ÄÕÍÁÌÇ ÃÉÁÔÉ ÌÐÏÑÏÕÌÅ ÍÁ ÆÇÓÏÕÌÅ ÌÅ ÔÏÍ HIV ÖÕÓÉÏËÏÃÉÊÁ.

ÄÕÓÔÕ×¿Ó Ç ÃÕÍÁÉÊÁ ÌÏÕ ÊÏËËÇÓÅ ÁÐÏ ÌÅÍÁ ÁËËÁ ÔÏ ÐÁÉÄÉ ÄÏÎÁ ÔÏÍ ÈÅÏ ÁÐÏ ÈÁÕÌÁ Ï×É.




... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Another step towards closing the paediatric treatment gap

Expanding access to antiretroviral therapy (ART) and reducing new HIV acquisitions among women has led to a marked decline in vertical HIV transmission over the past decade. Nevertheless, in 2023 alone, an estimated 120 000 children aged 0–14 years acquired HIV globally, with the vast majority living in Africa.1 Without treatment, over half of infants and young children with perinatally acquired HIV die before their second birthday.2 Early diagnosis and timely linkage to care are therefore essential to reducing morbidity and mortality.

Deworming of filariasis and reduction of HIV incidence

In sub-Saharan Africa, lymphatic filariasis and HIV infection are two major public health problems that often coexist.1 For several decades, scientists have been exploring the negative impact of helminth infections, including the filarial nematode Wucheria bancrofti, on HIV acquisition and pathogenesis.1–3 Immunological studies have tried to validate the anecdotal, but biologically plausible, theory that modulatory effects of helminths such as W bancrofti can affect HIV infection.3–5 However, some of these studies were inconclusive, and many were characterised by two common flaws, cross-sectional design1 or small sample size,3 weakening the strength of the evidence.

Modelling study shows staggering impact of HIV funding cuts

The global AIDS response has seen substantial reductions in HIV incidence and number of deaths.1 The greatest improvements have been recorded in sub-Saharan Africa, the region with the worst HIV burden. Many of the advances are attributed to international funding of national programmes within sub-Saharan Africa. International contributions were estimated to be 41% of total HIV expenditure in low-income and middle-income countries (LMICs) in 2023.1 Over the last 5–10 years there have been reported declines in HIV funding from both domestic contributions and non-US international funders.

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò

ÔçëåöùíéêÞ ãñáììÞ ãéá ôï HIV/AIDS

210-7222222

ÄåõôÝñá - ÐáñáóêåõÞ
09:00 - 21:00